{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', \"clinical laboratory tests, from the most recent clinic visit and will determine each candidate's\", 'suitability for the study. The Investigator must review these results before determining that a', 'candidate is eligible for study drug treatment. The Baseline urine pregnancy test performed for', 'all female candidates of childbearing potential must be negative in order for subjects to be', 'eligible for treatment. The following procedures will be performed at Baseline to establish each', \"candidate's general health and eligibility for enrollment into the study:\", 'Obtain signed, written informed consent and permission to use Protected Health', 'Information (in accordance with the Health Insurance Portability and Accountability Act', '[HIPAA]). Refusal to provide this permission excludes an individual from eligibility for', 'study participation. Record date informed consent was given and who conducted the', 'process on the appropriate source documentation.', 'Determine study eligibility through review of the inclusion/exclusion criteria (see', 'Section 9.3)', 'Obtain predose blood samples for hematology and chemistry (including thyroid, glucose,', 'and HbA1c) analysis (see Section 9.5.4.6 for details concerning test results and study', 'participation).', 'Collect predose blood samples for immunogenicity and PK testing.', 'Collect predose urine sample for urinalysis and also for a pregnancy test for females of', 'childbearing potential; the pregnancy test must be negative for the subject to receive', 'study drug.', 'Enquire about signs and symptoms within previous 2 weeks.', 'Enquire about prior medication use during the previous 2 weeks (see Table 9.1 for', 'restrictions regarding medications).', 'Perform predose physical and ophthalmic examinations.', 'Measure weight.', 'Perform predose 12-lead ECG.', 'Perform predose Baseline efficacy assessments (CAS, Clinical Measures of Severity', 'including proptosis, diplopia and motility restriction).', 'Administer the predose GO-QoL questionnaire.', 'Register enrollment in EDC, obtain study medication vial assignment and volume of', 'study drug to be administered.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 95 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Monitor vital signs prior to and at the end of the infusion. Additional vital sign', 'monitoring may be performed in the event of infusion-associated AEs (see', 'Section 9.5.4.3 for details).', 'Administer the first dose of study drug and record date, volume and rate of infusion, and', 'start/stop times of dosing.', 'Monitor subjects regarding treatment-emergent signs and symptoms.', 'Collect blood samples for PK analyses at the end of the infusion.', 'Subjects will be discharged from the study center after all of the Study Day 1 procedures have', 'been completed and will be contacted the following day to enquire about AEs and concomitant', 'medication use.', '9.5.6.2 Week 1', 'Collect blood samples for hematology and glucose testing (see Section 9.5.4.6 for details', 'concerning test results and study participation).', 'Collect blood sample for PK analyses. Record date/time of sample collection.', 'Perform physical and ophthalmic examinations, including vital signs.', 'Enquire about AEs and concomitant medication use.', 'Subjects will be released from the study center after all of the visit procedures have been', 'completed and instructed to return to the clinic at Week 3.', '9.5.6.3 Week 3', 'Obtain predose blood samples for hematology and chemistry (including thyroid, glucose,', 'but not HbAlc) analysis (see Section 9.5.4.6 for details concerning test results and study', 'participation).', 'Collect predose urine sample for urinalysis and also for a pregnancy test for females of', 'childbearing potential; the pregnancy test must be negative for the subject to receive', 'study drug.', 'Collect predose blood sample for immunogenicity and PK testing.', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Perform predose 12-lead ECG.', 'Obtain study medication vial assignment and volume of study drug to be administered', 'from EDC.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 96 of 118']\n\n###\n\n", "completion": "END"}